Year in Review RA 2019 - Rheumatology Advisor

RHEUM YIR RA 2019

YEAR IN REVIEW: RHEUMATOID ARTHRITIS

Upadacitinib Approved for Moderate to Severe RA

The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.